Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials

References

• Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pr Res Clin Obs Gynaecol 2004;18:671-83
   PubMed Web of Science ®Google Scholar
• Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9
   PubMed Web of Science ®Google Scholar
• Pasquali R, Stener-Victorin E, Yildiz BO, et al. PCOS Forum: research in polycystic ovary syndrome today and tomorrow. Clin Endocrinol 2011;74:424-33
   PubMed Web of Science ®Google Scholar
• Guzick D, York N. Polycystic ovary syndrome: symptomatology, pathophysiology, and epidemiology. Am J Obs Gynecol 1998;179:89-93
   Web of Science ®Google Scholar
• Park KH, Kim JY, Ahn CW, et al. Polycystic ovarian syndrome (PCOS) and insulin resistance. Int J Gynaecol Obstet 2001;74:261-7
   PubMed Web of Science ®Google Scholar
• Ehrmann D, Barnes R, Rosenfield R, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-6
   PubMed Web of Science ®Google Scholar
• Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010;16:347-63
   PubMed Web of Science ®Google Scholar
• Hoffman LK, Ehrmann DA. Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pr Endocrinol Metab 2008;4:215-22
   PubMedGoogle Scholar
• Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010;8:41-50
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004;82:661-5
   PubMed Web of Science ®Google Scholar
• Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002;77:1095-105
   PubMed Web of Science ®Google Scholar
• Azziz R, Dumesic DA, Chazenbalk G, Goodarzi MO. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011;7:219-31
   PubMed Web of Science ®Google Scholar
• Burt Solorzano CM, Beller JP, Abshire MY, et al. Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids 2012;77:332-7
   PubMed Web of Science ®Google Scholar
• Kirpichnikov D, Mcfarlane S, Sowers J. Metformin: an update. Ann Intern Med 2002;137:25-33
   PubMed Web of Science ®Google Scholar
• Wright JJ, Tylee TS. Pharmacologic therapy of type 2 diabetes. Med Clin North Am 2016;100:647-63
   PubMed Web of Science ®Google Scholar
• Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-54
   PubMed Web of Science ®Google Scholar
• Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic clinical evaluation. J Clin Endocrinol Metab 2014;85:139-46
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Wang P, Fontaine R, et al. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Heal 2001;29:160-9
   PubMed Web of Science ®Google Scholar
• Gao L, Zhao F, Li S. Statin is a reasonable treatment option for patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Exp Clin Endocrinol Diabetes 2012;120:367-75
   PubMed Web of Science ®Google Scholar
• Tang T, Lord J, Norman R, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012;5:1-160
   Google Scholar
• Du Q, Wang Y-J, Yang S, et al. A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. Curr Med Res Opin 2012;28:723-30
   PubMed Web of Science ®Google Scholar
• Naderpoor N, Shorakae S, De Courten B, et al. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Updat 2015;21:1-15
   Google Scholar
• Choi E, Yang Y. Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome. Ther Clin Risk Manag 2015;11:1345-53
   PubMed Web of Science ®Google Scholar
• Misso ML, Costello MF, Garrubba M, et al. Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2013;19:2-11
   PubMed Web of Science ®Google Scholar
• Cassina M, Dona M, Di Gianantonio E, et al. First-trimester exposure to metformin and risk of birth defectsâ: a systematic review and meta-analysis. Hum Reprod Updat 2014;20:656-69
   PubMed Web of Science ®Google Scholar
• Feng L, Lin X, Wan Z, et al. Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis. Gynecol Endocrinol 2015;31:833-9
   PubMed Web of Science ®Google Scholar
• Zhuo Z, Wang A, Yu H. Effect of metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis. J Diabetes Res 2014;1-13
   Web of Science ®Google Scholar
• Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327:951-3
   PubMed Web of Science ®Google Scholar
• Nieuwenhuis-Ruifrok AE, Kuchenbecker WKH, Hoek A, et al. Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Hum Reprod Update 2009;15:57-68
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1-34
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011
   Google Scholar
• Önalan G, Goktolga U, Ceyhan T, et al. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic? Eur J Obstet Gynecol Reprod Biol 2005;123:204-11
   PubMed Web of Science ®Google Scholar
• Maciel GAR, Soares JM, Alves Da Motta EL, et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004;81:355-60
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Jakubowicz DJ, Iuorno MJ, et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004;82:893-902
   PubMed Web of Science ®Google Scholar
• Bonakdaran S, Khorasani ZM, Davachi B, Khorasani JM. The effects of calcitriol on improvement of insulin resistance, ovulation and comparison with metformin therapy in PCOS patients: a randomized placebo-controlled clinical trial. Iran J Reprod Med 2012;10:465-72
   PubMedGoogle Scholar
• Chou K, Corleta H, Capp E, Spritzer P. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Horm Metab Res 2003;35:86-91
   PubMed Web of Science ®Google Scholar
• Eisenhardt S, Schwarzmann N, Henschel V, et al. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2006;91:946-52
   PubMed Web of Science ®Google Scholar
• Hoeger KM, Kochman L, Wixom N, et al. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004;82:421-9
   PubMed Web of Science ®Google Scholar
• Hoeger K, Davidson K, Kochman L, et al. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 2008;93:4299-306
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Russo T, et al. Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:3128-35
   PubMed Web of Science ®Google Scholar
• Guido M, Romualdi D, Giuliani M, et al. Effect of metformin on the growth hormone response to growth hormone-releasing hormone in obese women with polycystic ovary syndrome. Fertil Steril 2005;84:1470-6
   PubMed Web of Science ®Google Scholar
• Romualdi D, Giuliani M, Cristello F, et al. Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Fertil Steril 2010;93:2303-10
   PubMed Web of Science ®Google Scholar
• Kelly CJG, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 2002;147:217-21
   PubMed Web of Science ®Google Scholar
• Lord J, Thomas R, Fox B, Acharya U, Wilkin T.. The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome – a randomised , double-blind , placebo-controlled trial. BJOG 2006;113:817-24
   Google Scholar
• Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized , double-blinded , placebo-controlled cross-over trial. Hum Reprod 2007;22:2967-73
   Google Scholar
• Trolle B, Lauszus F, Frystyk J, et al. Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study. Fertil Steril 2010;94:2234-8
   PubMed Web of Science ®Google Scholar
• Costello MF, Eden JA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003;79:1-13
   PubMed Web of Science ®Google Scholar
• Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review. Br Med J 2003;327:1-6
   PubMed Web of Science ®Google Scholar
• Ferriman D, Gallwey JD. Clinical Assessment of Body Hair. J Clin Endocrinol Metab 1961;21:1440-7
   PubMed Web of Science ®Google Scholar
• Aubuchon M, Lieman H, Stein D, et al. Metformin does not improve the reproductive or metabolic profile in women with polycystic ovary syndrome (PCOS). Reprod Sci 2009;16:938-46
   Google Scholar
• Agarwal N, Rice SPL, Bolusani H, Luzio SD, Dunseath G, Ludgate M, et al. Metformin Reduces Arterial Stiffness and Improves Endothelial Function in Young Women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 2015;95:722-30
   Web of Science ®Google Scholar
• Fleming R, Wallace AM, Greer IA, Sattar NHZE. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002;87:569
   PubMed Web of Science ®Google Scholar